To determine whether the effect of IDR in promoting cytotoxicity applied to CARs beyond CD19, we constructed IDR CARs targeting HER2 (Fig. 3a), an antigen commonly overexpressed in multiple solid tumors including breast, ovarian, lung and colorectal cancers. Here, ERBB2 is linked to colorectal cancer.